
ChromaDex Corp (NAGE) Stock Forecast & Price Target
ChromaDex Corp (NAGE) Analyst Ratings
Bulls say
Niagen Bioscience is the leader in NAD+ science and healthy-aging research with a unique portfolio of over 100 patents and multiple growth opportunities. These include expansion of their core supplement business, rollout of Niagen IV and at-home injectable kits, and potential use cases in various diseases. Their recent financial results show strong revenue growth, and a recent lawsuit against the FDA could provide a long-term tailwind. Risks include potential slower-than-projected sales growth and unfavorable clinical data. Overall, with a strong portfolio and growth potential, Niagen Bioscience has a positive outlook for investors.
Bears say
Niagen Bioscience is heavily reliant on one key product, Tru Niagen. With the possibility of changes in consumer preferences, competition, and regulatory risks, as well as the potential for stock dilution, there are fundamental uncertainties that may negatively impact the company's revenue and overall financial performance in the coming quarters. The company's decision to expand into the telehealth market with the Niagen Plus platform may bring some operational efficiency, but it may not be enough to mitigate the risks facing their core product and overall business model. Without strong efforts to diversify their product offerings and build a more resilient business model, Niagen Bioscience may struggle to maintain its leadership in the NAD+ science industry and satisfy investor expectations for growth.
This aggregate rating is based on analysts' research of ChromaDex Corp and is not a guaranteed prediction by Public.com or investment advice.
ChromaDex Corp (NAGE) Analyst Forecast & Price Prediction
Start investing in ChromaDex Corp (NAGE)
Order type
Buy in
Order amount
Est. shares
0 shares